C-C chemokine receptor type 7 and C-C chemokine receptor type 10 (CCR7/CCR10)

The CCR7 and CCR10 signaling axis represents a critical pathway in the maintenance and metastatic potential of cancer stem cells (CSCs). CCR7 (C-C chemokine receptor type 7) and CCR10 (C-C chemokine receptor type 10) are G protein-coupled receptors that respond to specific chemokine ligands, such as CCL19/CCL21 and CCL27/CCL28, respectively (UniProt P32248; UniProt P46092). In the context of oncology, these receptors are often overexpressed on CSCs, where they facilitate organ-specific metastasis by mimicking the homing mechanisms of immune cells to lymph nodes and skin (Müller et al., 2001, Nature). Activation of these pathways triggers downstream signaling cascades, including the PI3K/Akt and MAPK/ERK pathways, which promote cell survival, epithelial-mesenchymal transition (EMT), and chemoresistance (Liu et al., 2021, Frontiers in Oncology). Targeting this dual signaling axis is an emerging therapeutic strategy aimed at disrupting the homing of CSCs to metastatic niches and sensitizing them to conventional therapies. While several small molecule antagonists and monoclonal antibodies are in various stages of preclinical and clinical development, challenges remain regarding the potential impact on normal immune cell trafficking and systemic homeostasis (Förster et al., 2008, Nature Reviews Immunology).

Other names

CCR7CCR10CD197GPR2CC-CKR-7CC-CKR-10CMKBR7EBI1

Antagonism of CCR7 and CCR10 receptors to inhibit chemokine-mediated migration and survival signaling.